Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. MDT
2. ENOV
3. AON
4. AZN
5. BLSM
6. GRMN
7. LTGO
8. KRMN
9. TXNM
10. JFB

Go back to Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'

UPDATE: JMP Securities Starts BioLineRx (BLRX) at Market Outperform

June 22, 2015 7:47 AM EDT

(Updated - June 22, 2015 8:58 AM EDT)

JMP Securities initiated coverage on BioLineRx (NASDAQ: BLRX) with a Market Outperform rating and a price target of $5.00. Analyst Michael King Jr thinks investors are undervaluating the company's pipeline, given four of six assets are in phase II... More